


## How Can I Evaluate A Medical Research Study





We Don't Really "Read" the Study

















Familiarize yourself with what to **evaluate**.


























# Is Reading This Study Worth Your Time?

### 1. Right study **design**???

- 2. If the results are reliable, are they **useful** and usable? Would they change your practice?
- Are the results in clinically significant areas? If not, is there a reliable causal chain of evidence to support use of an intermediate marker?
- 4. Were outcomes and analyses determined in advance?
- 5. Are **definitions** of outcomes such as success/failure, improvement/no improvement, etc. reasonable?
- 6. Are the confidence intervals wholly inclusive of clinical benefit? If non-significant, are the confidence intervals wholly exclusive of clinical benefit?
- 7. Is this a **new intervention**? If yes, safety is likely to be unknown.





## JOURNALIA MEDICUS HYPOTHETICALIA

Vol. 55, No. 2, April 1, 2012, pp 1225-1234 Delfini Group Publishing, LLC

Use of Myoceptimab, a New Smooth Muscle Surface Protein Inhibitor, for Treatment of Patients with Exercise-Related Coronary Artery Angina On Individualized Medical Therapy Pingle Handle S, Twister Michael E and Shuart Martha E. University of Delphinidae.

#### BACKGROUND

Myoceptimab is a smooth muscle cell proliferation inhibitor that affects coronary arterial blood flow and provides relief from angina.

#### METHODS

We conducted a randomized, double-blind trial MLC in 18 centers with similar populations in the US to assess the efficacy and safety of

USUC myoceptimab in patients aged 55 and older who had a history of coronary heart disease (CHD), exercise-related angina and were on what their physicians considered optimal medical therapy.


EKLPatients with a history of heart failure were INEL excluded. Eligible patients experienced at least three episodes of angina per week, were on optimal medical therapy as determined by their physicians for stable coronary artery disease of the trial regardless of their participation status.


### TNI


Patients were randomly assigned to receive 60 mg of myoceptimab or placebo daily for 36 Tp L<sup>J</sup> months utilizing a computer-generated 2 Pt <sup>J</sup> sequence. Allocation was concealed through *C* A maintained under the control of the Central Pharmacy Director who was not otherwise involved in the study. Assignment to study group was carried out utilizing local pharmacy personnel not aware of the study, objectives and not otherwise involved in the study.

Study medications were identical in both BWN groups in all aspects such as medication size, color, and taste. Myoceptimab and identical plaçebo were provided by the pharmaceutical companies without charge and were placed in identical capsules by Tech Inc., a laboratory not











- Fast pass is fast!
- Logs critical appraisal elements in your head as you go
- Answers to questions might be addressed later, so helps minimize just-in-time struggle
- Mark negative items, questions, need for action steps along with your entries as you go
- Review your checklist and add missing items as threats or questions to the top
- Advantages
  - Helps makes it fast to summarize your critical appraisal
  - Makes it easy to find elements of interest
  - Is your documentation











www.delfini.org Click on the book cover at our menu to Delfini Group Evidence-based Practice Series the left...



